This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adam's Most Recent Article

Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock

07/07/15 - 07:43 AM EDT

Short sellers -- "manipulative" or otherwise -- are not responsible for Keryx's withering stock price. The problem is Auryxia, the company's kidney dialysis drug.

read more >

Other Articles by Adam

Free Reports

Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed

07/07/15 - 07:29 AM EDT

Like other specialty pharmaceutical makers headquartered in tax-friendly countries, Horizon is buying growth.

read more >
Vertex Wins U.S. Approval for New Cystic Fibrosis Drug

07/02/15 - 02:36 PM EDT

The newly approved Vertex pill, taken twice per day, is targeted at a genetic defect found in almost half of cystic fibrosis patients.

read more >
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

07/02/15 - 12:54 PM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin

06/30/15 - 11:27 AM EDT

The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.

read more >
Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership

06/29/15 - 05:10 PM EDT

Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.

read more >
Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week

06/29/15 - 11:06 AM EDT

Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.

read more >
Sarepta Submits DMD Drug for FDA Approval Review

06/29/15 - 07:02 AM EDT

New Sarepta CEO Ed Kaye filed for approval of eteplirsen with the FDA as promised, allowing him to check off a hugely important item on the company's to-do list.

read more >
Biotech Stock Mailbag: Exelixis, Puma Bio

06/26/15 - 06:01 AM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
Alcobra Placebo Beats Drug in Failed Genetic Disease Study

06/24/15 - 10:13 AM EDT

Alcobra's MDX has now failed to demonstrate benefit for patients in two different clinical trials.

read more >
Page 1 of 337
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs